In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden

Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects. The activity of omadacycline and five comparators was assessed w...

Descripción completa

Detalles Bibliográficos
Autores principales: Camporeale, Angela, Tellapragada, Chaitanya, Kornijenko, Jelena, Nord, Carl Erik, Giske, Christian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Observation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510182/
https://www.ncbi.nlm.nih.gov/pubmed/34612686
http://dx.doi.org/10.1128/Spectrum.01440-21
Descripción
Sumario:Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects. The activity of omadacycline and five comparators was assessed with agar dilution on a 2015-to-2018 collection of 65 C. difficile isolates from Sweden. Omadacycline demonstrated in vitro activity against the contemporary ribotypes of C. difficile, and further clinical investigation is needed. IMPORTANCE Evaluating the activity of novel antimicrobials like omadacycline is of great interest, as a reliable and efficient antimicrobial treatment for Clostridioides difficile infections is in demand.

Ejemplares similares